Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 30-80~2. Parkinson disease~3. On dopamine agonists (Ropinirole IR or Pramipexole IR) and are considering to change into Ropinirole PR~4. On stable antiparkinsonian medication for at least 4 weeks~5. Who signed consent to the study~Exclusion Criteria:~1. Who are on less than 2 mg of Ropinirole IR or 0.375 mg of Pramipexole IR~2. Who have dementia, psychosis, major depression and other serious neurological or medical problems~3. Who are allergic to the similar medications~4. Who has history of heavy metal poisoning~5. Who were on othe clinical trials of other medications within the last 4 weeks~6. Whoa re pregnant or lactating~7. Who are considered not eligible by the investigator

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ropinirole PR QD first, then BID (Type: ACTIVE_COMPARATOR): Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
- Ropinirole PR BID first, and then QD (Type: ACTIVE_COMPARATOR): Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).